OUR PORTFOLIO
Active Portfolio Companies

4D Molecular Therapeutics is a gene therapy company with a transformative discovery platform – Therapeutic Vector Evolution – that enables invention of optimized and proprietary AAV vectors, each specifically designed to deliver genes to specific cells and tissues in the body, allowing treatment of diseases with high unmet medical needs. The company is currently focused on rare diseases of the eye, heart, muscle and lung.










Autobahn is a biotechnology company developing a pipeline of transformative small molecule therapies for the treatment of CNS disorders. The company’s lead program leverages a brain-targeting chemistry platform to target the unambiguous link between thyroid hormone and myelin biology for AMN and MS.


BioGraph 55 is an immuno-oncology target discovery and drug development company that uses advanced imaging analytics and machine learning to capture clinically relevant content from the tumor microenvironment.



BlueLight Therapeutics is a biotechnology company that uses a novel structure-function-based approach to develop new therapeutic molecules against challenging drug targets to treat a wide range of serious diseases.

Bolt is a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer. The company’s lead ISAC is delivered systemically as monotherapy for HER2-expressing cancers.



eFFECTOR is a clinical stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule drugs for treating cancer. The company’s investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR’s most advanced program focuses on the development of tomivosertib, which is in Phase 2 studies.


EvolveImmune is rapidly transforming the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets which are expressed on multiple immune cell types, with the aim to generate first-in-class treatments for unmet needs in oncology and autoimmune diseases.

FoRx is developing first-in-class small-molecule therapeutics that exploit the presence of DNA replication stress in human cancers.


Imara develops IMR-687, a preclinical phosphodiesterase-9 (PDE-9) inhibitor for sickle cell disease and other hemoglobinopathies. The company was granted exclusive global rights to Lundbeck's IMR687.




Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases by advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Using its protein degradation platform, the company is building a therapeutic pipeline in oncology and immunology.

Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain.



Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis. The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs.






Morphic Therapeutic is engaged in the discovery and development of a new generation of oral integrin drugs. Based on research conducted in the laboratory of the company’s founding scientist, Tim Springer, Morphic is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders and immune-oncology.

RESILIENCE is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale.





Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with superior therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies.









TRex Bio is a stealth mode, discovery-stage biotechnology company focused on making a meaningful difference in the lives of patients suffering from fatal or debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases. TRex aims to achieve this vision via functional manipulation of Tregs and other immune cells in a tissue-specific and disease-specific fashion.



Former Portfolio Companies







Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. The company is leveraging its differentiated endogenous nitrated fatty acid cell signaling technology platform, to focus on Focal Segmental Glomerulosclerosis (FSGS) and Pulmonary Arterial Hypertension (PAH). Complexa believes its approach has the ability to not only halt, but to reverse, disease related fibrosis. The company’s lead product CXA-10 is in Phase 2 trials.

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue.










M2S is a pioneer and leader in imaging and data management technology. They were the first to develop and market 3-D imaging technology to vascular surgeons. Their Preview product is still the market leader in this field. In 2006, the company expanded into providing core lab services for clinical trials and customized data registries for physicians, hospitals, medical centers, and clinical researchers


NeuMoDx is developing a next generation testing platform for the in vitro molecular diagnostic (MDx) market. The product vision is to create a walk-away bench-top system that combines sensitivity, high speed (time to first result and throughput), low cost, and random access, in an “open” architecture that can support both IVDs and Lab Developed Tests (LDTs).





Petra Pharma is a drug development company focused on novel enzyme targets that play a central role in a variety of important cellular processes, including cell division, growth, trafficking, and signaling. Petra Pharma will develop novel small molecules for the treatment of cancer and metabolic diseases to target these cellular processes in order to therapeutically impact human health.


Simcha Therapeutics is an early stage biopharmaceutical company with a focus on developing next generation cytokine immunotherapies to trigger the immune system to fight disease, particularly cancers. The company was incorporated in 2018 and is based in New Haven, Connecticut.






